Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

Abstract: Pharmaceutical and chemical intermediates and relevant chemicals, and relates to a novel preparation method of N-substituted dibenzo[a,c]carbazole compound. O-alkynylaniline and derivatives thereof as raw materials conduct a cascade cyclization reaction in an anhydrous organic solvent in the presence of catalysts, oxidants and additives, and are converted into the N-substituted dibenzo[a,c]carbazole compound. The preparation method of the N-substituted dibenzo[a,c]carbazole compound has fewer reaction steps, low cost of raw material, mild reaction conditions and convenient operation. Moreover, the obtained product has high yield and high purity, fully meets the quality requirements for drug intermediates, and provides favorable conditions for the industrial production.

Abstract: Pharmaceutical and chemical intermediates and relevant chemicals, and relates to a novel preparation method of N-substituted dibenzo[a,c]carbazole compound. O-alkynylaniline and derivatives thereof as raw materials conduct a cascade cyclization reaction in an anhydrous organic solvent in the presence of catalysts, oxidants and additives, and are converted into the N-substituted dibenzo[a,c]carbazole compound. The preparation method of the N-substituted dibenzo[a,c]carbazole compound has fewer reaction steps, low cost of raw material, mild reaction conditions and convenient operation. Moreover, the obtained product has high yield and high purity, fully meets the quality requirements for drug intermediates, and provides favorable conditions for the industrial production.

Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

Abstract: A fullerene derivative represented by the following formula (1): wherein “FLN” represents a fullerene core, R1 represents an optionally substituted C1-C24 alkyl group or an optionally substituted C7-C24 aralkyl group, R2 and R3 independently represent a hydrogen atom or an optionally substituted C1-C24 hydrocarbon group but excluding a case where both of R2 and R3 are hydrogen atoms, and R2 and R3 may combine together to form a ring.

Abstract: Disclosed is a fullerene derivative represented by the following formula (1): wherein FLN is a fullerene backbone, R1 is a substituted or non-substituted alkyl group with a carbon number less than or equal to 24, and Ar1 is a substituted or non-substituted aryl group with a carbon number less than or equal to 24.

Abstract: Disclosed is a fullerene derivative represented by the following formula (1): wherein FLN is a fullerene backbone, R1 is a substituted or non-substituted alkyl group with a carbon number less than or equal to 24, and Ar1 is a substituted or non-substituted aryl group with a carbon number less than or equal to 24.

Abstract: A fullerene derivative represented by the following formula (1): wherein “FLN” represents a fullerene core, R1 represents an optionally substituted C1-C24 alkyl group or an optionally substituted C7-C24 aralkyl group, R2 and R3 independently represent a hydrogen atom or an optionally substituted C1-C24 hydrocarbon group but excluding a case where both of R2 and R3 are hydrogen atoms, and R2 and R3 may combine together to form a ring.

Abstract: This invention provides a novel immunotolerance inducer which is effective in inducing immunological tolerance without involving any remarkable invasive procedure, thus ensuring the maintenance of a transplanted organ without administration of an immunosuppressant drug.